The Emerging Role of Pharmacomicrobiomics in Pharmacovigilance: Gut Microbiome as A Determinant of Drug Safety
1
Department Of Pharmacology, Dr. Rajendra Gode College of Pharmacy, Amravati 444602, Maharashtra India
Received: 2025-09-21
Revised: 2025-09-30
Accepted: 2025-10-22
Published: 2025-11-12
Pharmacomicrobiomics, the study of interactions between the gut microbiome and drugs, is emerging as a key factor in pharmacovigilance and drug safety evaluation. Traditional adverse drug reaction (ADR) detection methods often overlook individual microbial variability that significantly influences drug metabolism, efficacy, and toxicity. This review highlights the gut microbiome’s pivotal role as a determinant of drug safety, exploring its mechanism in modulating drug responses and adverse effects. The integration of phramacovigilance into personalized pharmacovigilance frameworks promises to enhance ADR prediction and prevention by considering individual microbiome profiles. Additionally, this article addresses regulatory and ethical considerations associated with microbiome data usage in drug safety monitoring. Future perspectives include overcoming challenges such as standardization, microbiome complexity, and data integration to fully realize personalized, microbiome-informed phramacovigilanc
Pharmacomicrobiomics, Gut Microbiome, Phramacovigilance, Adverse Drug Reactions, Drug Safety.